Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: Neuromuscul Disord. 2015 May 27;25(9):699–705. doi: 10.1016/j.nmd.2015.05.008

Figure 2.

Figure 2

Oral administration of D156844 augmented the follistatin-induced increase in the onset of loss in body mass of SMNΔ7 SMA mice. Kaplan-Meier onset of body mass loss plot for SMNΔ7 SMA mice receiving either vehicle (light gray dotted line; n = 17), 1 mg/kg/qad follistatin (gray dashed line; n = 20) or a combination of 3 mg/kg/d D156844 and 1 mg/kg/qad follistatin (solid line; n = 23). Treatment of SMNΔ7 SMA mice began at PND04.